139 related articles for article (PubMed ID: 33461147)
41. Expression and crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibility molecules.
Gastinel LN; Simister NE; Bjorkman PJ
Proc Natl Acad Sci U S A; 1992 Jan; 89(2):638-42. PubMed ID: 1530991
[TBL] [Abstract][Full Text] [Related]
42. Impact of IgG2 high molecular weight species on neonatal Fc receptor binding assays.
Zhang Y; Mathur A; Maher G; Arroll T; Bailey R
Anal Biochem; 2015 Nov; 489():25-31. PubMed ID: 26255698
[TBL] [Abstract][Full Text] [Related]
43. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.
Ying T; Chen W; Feng Y; Wang Y; Gong R; Dimitrov DS
J Biol Chem; 2013 Aug; 288(35):25154-25164. PubMed ID: 23867459
[TBL] [Abstract][Full Text] [Related]
44. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
[TBL] [Abstract][Full Text] [Related]
45. Quantitative methods for developing Fc mutants with extended half-lives.
Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA
Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591
[TBL] [Abstract][Full Text] [Related]
46. Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis.
Hornby PJ; Cooper PR; Kliwinski C; Ragwan E; Mabus JR; Harman B; Thompson S; Kauffman AL; Yan Z; Tam SH; Dorai H; Powers GD; Giles-Komar J
Pharm Res; 2014 Apr; 31(4):908-22. PubMed ID: 24072267
[TBL] [Abstract][Full Text] [Related]
47. V Region of IgG Controls the Molecular Properties of the Binding Site for Neonatal Fc Receptor.
Rossini S; Noé R; Daventure V; Lecerf M; Justesen S; Dimitrov JD
J Immunol; 2020 Nov; 205(10):2850-2860. PubMed ID: 33077645
[TBL] [Abstract][Full Text] [Related]
48. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
[TBL] [Abstract][Full Text] [Related]
49. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
50. Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.
Wilkinson IC; Fowler SB; Machiesky L; Miller K; Hayes DB; Adib M; Her C; Borrok MJ; Tsui P; Burrell M; Corkill DJ; Witt S; Lowe DC; Webster CI
MAbs; 2013; 5(3):406-17. PubMed ID: 23567207
[TBL] [Abstract][Full Text] [Related]
51. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
[TBL] [Abstract][Full Text] [Related]
52. The potential of porcine ex vivo platform for intestinal permeability screening of FcRn-targeted drugs.
Azevedo C; Andersen JT; Traverso G; Sarmento B
Eur J Pharm Biopharm; 2021 May; 162():99-104. PubMed ID: 33771621
[TBL] [Abstract][Full Text] [Related]
53. Expression of neonatal Fc receptor in the eye.
Powner MB; McKenzie JA; Christianson GJ; Roopenian DC; Fruttiger M
Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1607-15. PubMed ID: 24550358
[TBL] [Abstract][Full Text] [Related]
54. Soluble monomeric IgG1 Fc.
Ying T; Chen W; Gong R; Feng Y; Dimitrov DS
J Biol Chem; 2012 Jun; 287(23):19399-408. PubMed ID: 22518843
[TBL] [Abstract][Full Text] [Related]
55. Toward systems-informed models for biologics disposition: covariates of the abundance of the neonatal Fc Receptor (FcRn) in human tissues and implications for pharmacokinetic modelling.
Barber J; Al-Majdoub ZM; Couto N; Howard M; Elmorsi Y; Scotcher D; Alizai N; de Wildt S; Stader F; Sepp A; Rostami-Hodjegan A; Achour B
Eur J Pharm Sci; 2023 Mar; 182():106375. PubMed ID: 36626943
[TBL] [Abstract][Full Text] [Related]
56. NF-kappaB signaling regulates functional expression of the MHC class I-related neonatal Fc receptor for IgG via intronic binding sequences.
Liu X; Ye L; Christianson GJ; Yang JQ; Roopenian DC; Zhu X
J Immunol; 2007 Sep; 179(5):2999-3011. PubMed ID: 17709515
[TBL] [Abstract][Full Text] [Related]
57. Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor.
Feng Y; Gong R; Dimitrov DS
Protein Expr Purif; 2011 Sep; 79(1):66-71. PubMed ID: 21453773
[TBL] [Abstract][Full Text] [Related]
58. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,).
West AP; Bjorkman PJ
Biochemistry; 2000 Aug; 39(32):9698-708. PubMed ID: 10933786
[TBL] [Abstract][Full Text] [Related]
59. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.
Porter C; Armstrong-Fisher S; Kopotsha T; Smith B; Baker T; Kevorkian L; Nesbitt A
J Reprod Immunol; 2016 Aug; 116():7-12. PubMed ID: 27123565
[TBL] [Abstract][Full Text] [Related]
60. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
